Metabolomics analysis reveals cytotoxic effects of ouabain towards psoriatic keratinocytes via impairment of glutathione metabolism

Mol Genet Genomics. 2023 May;298(3):567-577. doi: 10.1007/s00438-023-02001-9. Epub 2023 Mar 1.

Abstract

Ouabain is a cardiac glycoside long studied for treating heart diseases, but the attempts to evaluate its anti-psoriatic activity have not been reported. We aimed to explore the effects of ouabain on proliferation and metabolism towards psoriatic keratinocytes. In human HaCaT keratinocytes, ouabain potently decreased viability, promoted apoptosis and caused G2/M cycle arrest. Metabolomics analysis indicated that ouabain markedly impaired glutathione metabolism. The solute carrier family 7 member 11 (SLC7A11) is an amino acid transporter highly specific to cysteine, which is critical for glutathione synthesis. Ouabain downregulated SLC7A11, reduced cysteine uptake and subsequently inhibited glutathione synthesis, probably through inhibiting Akt/mTOR/beclin axis that regulate protein activity of SLC7A11. The impaired glutathione synthesis and oxidative stress caused by ouabain may contribute to its cytotoxicity towards psoriatic keratinocytes. Our results provide experimental evidence supporting further study of ouabain as a potential anti-psoriatic agent.

Keywords: Glutathione metabolism; Keratinocyte; Metabolomics; Ouabain; Psoriasis.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Apoptosis
  • Cell Proliferation
  • Cysteine / metabolism
  • Cysteine / pharmacology
  • Cysteine / therapeutic use
  • Glutathione / metabolism
  • Humans
  • Keratinocytes / metabolism
  • Ouabain / metabolism
  • Ouabain / pharmacology
  • Ouabain / therapeutic use
  • Psoriasis* / drug therapy
  • Psoriasis* / genetics

Substances

  • Ouabain
  • Cysteine
  • Antineoplastic Agents
  • Glutathione